Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer

Breast Cancer Clinical Trial

— NEST  

Official title:

A Phase III, Open-Label, Prospective, Randomized, Multicenter, Neo-adjuvant Study of Chemotherapy Versus Endocrine Therapy in Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01622361
• Other study ID #: KBCSG012
• Status: Recruiting
• Phase: Phase 3
• First received: June 13, 2012
• Last updated: September 26, 2013
• Start date: June 2012
• Est. completion date: February 2016

Study information

• Verified date: September 2013
• Source: Asan Medical Center
• Contact: Ahn Sei Hyun, MD.PhD
• Phone: 82-2-3010-3490
• Email: ahnsh[@]amc.seoul.kr
• Is FDA regulated: No
• Health authority: Korea: Food and Drug AdministrationKorea: Institutional Review BoardUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare neo-adjuvant therapy of cytotoxic chemotherapy versus GnRHa with tamoxifen , of response rate(RR) in patients of hormone responsive and HER2 negative, lymph node positive, primary breast cancer in premenopausal women.

Description:

1. Primary objective

: Response Rate-MRI and/or Caliper

2. Secondary objectives

• Pathologic complete response

• Rate of conservation surgery

• Ki-67 changes and its relationship to treatment response

• Length of time to maximum response within the treatment period

• Tolerability of two treatments

• Disease-free survival(DFS)

• Overall survival

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 290
• Est. completion date: February 2016
• Est. primary completion date: February 2016
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Histologically proven primary invasive breast cancer which is thought to be suitable for neo-adjuvant treatment

2. Pathologically proven lymph node positive tumor(FNAB or Core biopsy)

3. Tumor must be ER positive(eligible patients include Allred score 5 and more, Modified Allred 4 and more) and HER-2 negative(IHC score is 0-1+; If IHC score is 2+, the result of FISH or SISH is negative)

4. Premenopausal women

Premenopausal status as defined by :

• Last menses within 6 month of randomization or

• For patients who have had a unilateral oophorectomy, E2 = 20PG/mL and FSH < 30mIU/Ml within 4 weeks of randomization

5. over 20 years old

6. Pre-treatment haematology and biochemistry values within acceptable limits :

• ANC = 1.5 × 109/l

• Hb > 9g/dl

• Platelets = 100 × 109/l

• AST/ALT = 1.5 × ULN(Upper Limit of Normal)

• ALP = 1.5 × ULN

• Serum bilirubin = 1.5 × ULN

• Serum creatinine = 1.5 × ULN

7. ECOG PS of 0 or 1

8. No concomitant medical, psychiatric or geographic problems that might prevent completion of treatment or follow-up

9. Before any study-specific procedures, the appropriate written informed consent must be obtained

Exclusion Criteria:

1. Inflammatory breast cancer

2. Inoperable disease that is judged very unlikely to be rendered operable by neo-adjuvant treatment

3. Known severe hypersensitivity to GnRHa treatment

4. Bilateral invasive breast cancer

5. Other serious illness or medical condition:

• congestive heart failure or unstable angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or high-risk uncontrolled arrhythmias

• history of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent

• active uncontrolled infection

6. HRT within 4 weeks of starting treatment

7. Definite contra-indications for the use of corticosteroids.

8. Last 10 years with a history of other malignant tumor (except in the case of basal cell carcinoma or cervical carcinoma in situ, and where treatment consisted solely of resection)

9. Systemic metastatic (Tests for the diagnosis of systemic metastatic comply with the guideline in each institution)

10. Pregnant or breastfeeding women

11. Chronic oral treatment with corticosteroids unless initiated > 6 months prior to study entry and at low dose (= 20 mg methylprednisolone or equivalent).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Adriamycin+Cyclophosphamide>Docetaxel
Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2 Route: by slow intravenous bolus Schedule: every 3weeks for 4 cycle Docetaxel 75mg/m2 Route: intravenous as per local practice Schedule: every 3weeks for 4 cycle
• GnRHa with Tamoxifen
Goserelin(GnRHa) 3.6mg Route: subcutaneously under the abdominal skin Schedule: every 4weeks for 6cycles (period of 34 days between 2 administrations must not be exceeded) Tamoxifen 20mg/day Route: Oral Schedule: everyday

Locations

Country	Name	City	State
Korea, Republic of	Asan Medical Center	Seoul	Songpa-gu

Sponsors (2)

Lead Sponsor	Collaborator
Asan Medical Center	Korean Breast Cancer Study Group

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response Rate		6 months	Yes
Secondary	Pathologic complete response		6 months	Yes